NCT00561743View on ClinicalTrials.gov

A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Multiple Myeloma
Interventions
DRUG

Bortezomib + pegylated liposomal doxorubicin HCl + dexamethasone

All Listed Sponsors
lead

Janssen-Ortho Inc., Canada

INDUSTRY

NCT00561743 - A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients | Biotech Hunter | Biotech Hunter